Centre of Excellence for Women´s Health, E311-4500 Oak Street, Vancouver, BC V6H 3N1, Canada.
School of Population and Public Health, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Int J Environ Res Public Health. 2020 Jan 30;17(3):872. doi: 10.3390/ijerph17030872.
There is evidence that sex- and gender-related factors are involved in cannabis patterns of use, health effects and biological mechanisms. Women and men report different cannabis use disorder (CUD) symptoms, with women reporting worse withdrawal symptoms than men. The objective of this systematic review was to examine the effectiveness of cannabis pharmacological interventions for women and men and the uptake of sex- and gender-based analysis in the included studies. Two reviewers performed the full-paper screening, and data was extracted by one researcher. The search yielded 6098 unique records-of which, 68 were full-paper screened. Four articles met the eligibility criteria for inclusion. From the randomized clinical studies of pharmacological interventions, few studies report sex-disaggregated outcomes for women and men. Despite emergent evidence showing the influence of sex and gender factors in cannabis research, sex-disaggregated outcomes in pharmacological interventions is lacking. Sex- and gender-based analysis is incipient in the included articles. Future research should explore more comprehensive inclusion of sex- and gender-related aspects in pharmacological treatments for CUD.
有证据表明，性别因素与大麻的使用模式、健康影响和生物学机制有关。女性和男性报告的大麻使用障碍（CUD）症状不同，女性的戒断症状比男性更严重。本系统评价的目的是检查大麻药物干预对女性和男性的有效性，以及纳入研究中基于性别的分析的采用情况。两名审查员进行了全文筛选，一名研究人员提取了数据。搜索产生了 6098 条独特的记录——其中，有 68 条进行了全文筛选。有 4 篇文章符合纳入标准。从药物干预的随机临床试验中可以看出，很少有研究报告女性和男性的性别分类结果。尽管有新出现的证据表明性和性别因素在大麻研究中的影响，但药物干预中缺乏性别分类结果。纳入的文章中基于性别的分析刚刚起步。未来的研究应该探索在 CUD 的药物治疗中更全面地纳入与性和性别相关的方面。
